Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome BioscienceTSE:4583 -1.43%38 Gross Margin % is 67.76% as of Dec. 2025, which is 19% above its 10-year median of 56.93. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 733 Biotechnology companies, Chiome Bioscience ranks worse than 51.16% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Chiome Bioscience had a gross margin of 67.76% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Chiome Bioscience Gross Margin % Related Terms
Chiome Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Chiome Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Chiome Bioscience (TSE:4583) has a Gross Margin % of 67.76% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Chiome Bioscience and its competitors. This is 19% above median its historical median of 56.93. Over the past decade, Chiome Bioscience's Gross Margin % has ranged from 45.36 to 67.11. According to the industry distribution chart, Chiome Bioscience ranks #375 out of 733 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Chiome Bioscience's Gross Margin % too high?
Chiome Bioscience's current Gross Margin % of 67.76% is 19% above median its 10-year median of 56.93. Over the past 10 years, this metric has ranged from a low of 45.36 to a high of 67.11. The Biotechnology industry median Gross Margin % is 60.90. Chiome Bioscience's value of 67.76% is 11.3% above this industry median. Based on the distribution chart, Chiome Bioscience ranks #375 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #375 out of 733 companies for Gross Margin %. This places Chiome Bioscience in the lower half of its industry. The industry median Gross Margin % is 60.90. Chiome Bioscience's value of 67.76% is 11.3% above this benchmark. Historically, Chiome Bioscience's own Gross Margin % has ranged from 45.36 to 67.11 over the past decade. While the company's 10-year median is 56.93 vs. the industry median of 60.90, Chiome Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Gross Margin % of 67.76% is 11.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Gross Margin % is 67.76%, which is 19% above median its own 10-year median of 56.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current Gross Margin % is 67.76%, which is 19% above median its 10-year median of 56.93 and 11.3% above the Biotechnology industry median of 60.90. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Gross Margin % is 67.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02.
GuruFocus considers Chiome Bioscience to be Possible Value Trap.
Key valuation signals for TSE:4583:
Gross Margin %: 67.76% (19% above median its 10-year median of 56.93)
GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
Industry Position: 11.3% above the Biotechnology median (#375 of 733)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score
Get the complete analysis for TSE:4583
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
